Objectives: To develop a novel b-galactosidase leakage assay for Staphylococcus aureus and to evaluate this alongside other simple methods for detection of agents that cause membrane damage in staphylococci.
Introduction
Infections caused by antibiotic-resistant strains of Staphylococcus aureus are increasing in both hospital and community settings. 1 Consequently, there has been considerable interest in discovering and developing new antistaphylococcal agents for potential therapeutic application. 1 However, during the search for novel antistaphylococcal agents, a number of synthetic and natural products have been identified that damage the staphylococcal cytoplasmic membrane. 2 -6 A consensus has now emerged that such agents should be eliminated from further study because their non-specific bactericidal activity usually corresponds to lack of prokaryotic specificity and therefore the likelihood of toxicity in mammals. 7, 8 A number of simple assays have been developed to detect membrane damage in S. aureus. These range from tests for alterations in membrane permeability such as the BacLight assay which measures changes in the uptake of fluorescent dyes, 2, 3, 5 to those that detect gross destruction of the cytoplasmic membrane through lysis of protoplasts. 2 However, a direct comparison of the various methods for detection of staphylococcal membranedamaging agents has not been published. In this paper we evaluate several techniques including the BacLight assay, methods to detect release of low molecular components from the cell and the protoplast lysis assay.
Release of the intracellular enzyme b-galactosidase is a traditional method for studying membrane-damaging agents in Escherichia coli. 7 However, this methodology has not been JAC available for staphylococci. In this paper, we report the development of a novel staphylococcal b-galactosidase leakage assay, which we have also evaluated alongside the other rapid methods for detection of membrane-damaging agents in S. aureus.
Materials and methods
Bacterial strains, reagents and antibacterial agents S. aureus 8325-4 was used as the standard test strain, although the restriction-deficient 8325-4 derivative, RN4220, was used for construction of a b-galactosidase-expressor (see below). All reagents, unless otherwise indicated, were purchased from Sigma -Aldrich (Poole, UK). Ciprofloxacin and protegrin IB-367 were gifts, respectively, from Bayer AG (Leverkusen, Germany) and IntraBiotics Pharmaceuticals (Mountain View, CA, USA).
Generation of an S. aureus strain strongly expressing b-galactosidase
In order to achieve high-level constitutive expression of b-galactosidase in S. aureus, the E. coli lacZ gene was placed under the control of the strong staphylococcal promoter, cap1A, using a PCR-based approach. These primers were used to PCR amplify the lacZ gene from plasmid pMC1871 (CBS, Utrecht, The Netherlands), using Platinum Pfx (Invitrogen, Paisley, UK), and a touchdown cycling approach [initial denaturation cycle at 948C for 2 min, followed by five cycles of denaturation at 948C for 15 s, annealing at 608C (dropping 18C per cycle) for 30 s and extension at 688C for 3 min, and then by 25 cycles of denaturation at 948C for 15 s, annealing at 558C for 30 s and extension at 688C for 3 min]. The resulting amplicon was ligated into pJIM2246 10 following restriction digestion with SalI/SpeI, and electroporated into S. aureus RN4220. Transformants expressing b-galactosidase were identified on agar containing X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside), and a single strain (AJ22) subjected to confirmatory DNA sequencing of the promoter/ lacZ junction.
b-Galactosidase leakage assay
Strain AJ22 was grown at 378C with aeration in Mueller -Hinton broth (MHB) containing chloramphenicol (25 mg/L) to an OD 600 of 0.6. Cells were resuspended in fresh MHB, and 225 mL of cell suspension was added to 25 mL of drug to achieve a final concentration of 4Â MIC. These mixtures were incubated at 258C for 10 min, before centrifuging at 16 000 g for 3 min to pellet cells. Aliquots (180 mL) of the supernatant were added to 20 mL of 4-methylumbelliferyl-b-D-galactoside (10 mg/mL in DMSO). Reaction mixtures were incubated at 258C for 100 min in black 96-well microtitre plates and fluorescence measured (excitation, 365 nm; emission, 460 nm). Relative fluorescence units were converted using a calibration curve generated from serial dilution of the fluorophore (4-methylumbelliferone).
Other assays for membrane damage
Previously-employed procedures were followed for assessing membrane damage by protoplast lysis, 2 leakage of material absorbing at 260 nm, 3 ATP release, 3 and the BacLight assay. 2, 5 In each case, cells were exposed to antibacterial agents at 4Â MIC for 10 min at 258C. Where applicable, independent readings were also taken only in the presence of antibacterial agents to enable corrections for background contributions to be made.
Results and discussion
b-Galactosidase (BG) leakage was quantified in the presence of control compounds (ciprofloxacin and tetracycline), and compounds known to cause membrane damage [cetyltrimethylammonium bromide (CTAB), nisin, clofazimine and protegrin IB-367 (PRO)]. Membrane damage caused by these compounds was also examined by quantifying protoplast lysis (PL), leakage of material absorbing at 260 nm (OD), ATP release, and by the BacLight (BL) assay.
No substantial membrane damage was detected in bacteria exposed to tetracycline and ciprofloxacin (Table 1) , as expected for agents with intracellular targets. All the assays, with the exception of the PL assay, detected membrane damage for CTAB, nisin and PRO, but the ability to detect membrane damage induced by these compounds differed between the assay systems ( Table 1) . For example, the ATP and BG assays most readily detected damage induced by nisin, whilst the OD and PL assays appeared to be superior for PRO and clofazimine, respectively. In contrast, clofazimine appears to exert only a weak membrane-disrupting effect as measured by the BL and BG assays (Table 1 ). In the case of the latter assay, the amount of membrane damage is presumably insufficient to allow release of the relatively large BG protein (molecular weight, 464 kDa) from the cytoplasm. This suggests that the BG assay will not identify compounds that only exert subtle membrane perturbations.
The assays varied considerably in their signal-to-noise ratio. The BG and OD assays displayed 5-10-fold greater activity in the presence of some membrane-disrupting agents relative to the control (no drug; Table 1 ), whilst the BL assay achieved slightly higher discrimination (10-20-fold; data not shown). The ATP assay enabled by far the greatest discrimination, with values for nisin approaching 100-fold that of the control. The low discriminatory power of the PL assay (Table 1) , and the inability of this assay to detect several membrane-damaging agents, suggests that it is unsatisfactory for quantifying membrane damage in S. aureus.
When considering the application of these assays in the industrial setting for potential high-throughput screening of large numbers of compounds, several factors need to be considered. These include the ability of the assays to detect agents with a range of membrane perturbing activities, their ease of use, their cost to perform, and their amenability to miniaturization for use in microtitre plate formats. In our opinion, the best assay was the OD assay, since it was effective, rapid and cheap to perform. The ATP, BL and BG assays all performed well and may be suited to particular types of experimental work. Studies requiring maximum sensitivity and discrimination should employ the ATP assay.
Several other established assay systems are available for the study or detection of membrane perturbation, such as phosphate or potassium leakage. 11 However, we obtained unreliable results for phosphate leakage (data not shown), and did not include measurement of potassium leakage since it is relatively complex and not readily amenable to high-throughput applications.
Finally, it should be noted that agents specifically inhibiting staphylococcal peptidoglycan synthesis promote cell lysis that will result in release of cellular components such as those detected in the OD, ATP and BG assays described here. However, at the screening stage, such agents can be readily distinguished from membrane-damaging agents by a number of simple assays including their failure to lyse organisms in which the stringent response is induced, 2,7 their specificity for peptidoglycan synthesis as judged by radiolabel incorporation, 12 their lack of activity against staphylococcal L forms, 12 and by their ability to induce the formation of osmotically fragile spheroplasts. 12 
